ClinicalTrials.gg
CompletedNCT00502996Updated Oct 14, 2016Results posted

A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.

A Phase 3 interventional study of Methotrexate and rituximab [MabThera/Rituxan] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 50 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-14.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
42nd of 113
246 · median 130
Started
2006
with 4 others
Phase 3
47 of 113
1 open now
Registered
22nd of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 42nd largest by enrollment, is one of 5 that started in 2006, is one of 47 in phase 3, and was the 22nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This single arm study will assess the safety of MabThera plus methotrexate in patients with rheumatoid arthritis who have had a lack of response to 1-5 DMARDs or biological agents. Patients will receive MabThera (1g i.v.) on days 1 and 15, concomitantly with methotrexate >=15mg p.o./week. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • rheumatoid arthritis >=6 months;
  • lack of response to 1-5 DMARDs or biological agents;
  • rheumatoid factor positive.

Exclusion criteria

Exclusion Criteria:

  • other chronic inflammatory articular disease or systemic rheumatic disease;
  • joint or bone surgery during 8 weeks prior to randomization;
  • previous treatment with any cell-depleting therapy.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
246 participants (actual)

Study arms

  • Experimental
    Rituximab

    Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.

    Drug: Methotrexate · Drug: rituximab [MabThera/Rituxan]

Interventions

  • \>=15 mg po/week

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1g iv on days 1 and 15

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event, Any Serious Adverse Event, and Death

    An Adverse event (AE) was considered any unfavorable medical event in a participant of clinical research who received the study drug and that not necessarily had a causal relationship with this treatment. An AE could, therefore, being any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. A serious adverse event (SAE) is any experience that suggested a significant risk, contraindication, caution, and at any dose fulfills at least one of the following criteria: adverse event considered as fatal (resulting in death), life threatening, defect of birth/congenital abnormality, required hospitalization or extension of hospital length of stay, significant medical intervention, resulted in significant disability/impairment.

    Time frame: Up to Week 48

  2. Number of Participants With AEs According to Degree of Intensity

    An AE is any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. The Intensity of AEs was classified as Grade 1, Grade 2, Grade 3 and Grade 4. Grade 1: Discomfort was noticed, but the normal daily activity was not interrupted. Grade 2: Discomfort was enough to reduce the normal daily activity. Grade 3: There was disability for work or develop normal daily activities. Grade 4: It represented an immediate threat to life (these events were reported as SAEs).

    Time frame: Up to Week 48

  3. Number of Participants With AEs Leading to Discontinuation and Any Drug Related AEs and SAEs

    An AE is any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. A SAE is any experience that suggested a significant risk, contraindication, caution, and at any dose, fulfills, at least, one of the following criteria: adverse event considered as fatal (resulting in death), life threatening, defect of birth/congenital abnormality, required hospitalization or extension of hospital length of stay, significant medical intervention, resulted in significant disability/impairment. Relationship between AEs and medication under investigation was evaluated through the classification "Yes" and "No". A relationship classified as "Yes" implied a significant causal relationship with the medication under investigation which was evaluated based on enough evidences, facts or arguments.

    Time frame: Up to Week 48

  4. Number of Participants With AEs of Special Interest During the Study

    Adverse event of special interest during the study treatment and follow up period included infections. The participants with AEs of special interest were reported at Screening, End of treatment (EOT), and End of Follow-up (EOFU) visit.

    Time frame: Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)

Secondary outcomes

  1. Mean Values of Hematology Parameters at Screening and EOT Visit (Hemoglobin and Mean Corpuscular Hemoglobin Concentration)

    The values of hemoglobin (Hb) and mean corpuscular hemoglobin concentration (MCHC) for each participant were estimated at Screening and at EOT visit.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  2. Mean Values of Hematology Parameters at Screening and EOT Visit (Hematocrit, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)

    The hematology parameters (hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) for each participant were estimated at Screening and at EOT.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  3. Mean Values of Hematology Parameter at Screening and EOT Visit (Mean Corpuscular Volume)

    Mean corpuscular volume (MCV) is the average volume of red cells. The mean MCV concentration for each participant was estimated at Screening and EOT.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  4. Mean Values of Hematology Parameter at Screening and EOT Visit (Erythrocytes)

    The mean erythrocyte concentration for each participant was estimated at Screening and at EOT.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  5. Mean Values of Hematology Parameters at Screening and EOT Visit (Leucocytes and Platelets)

    The mean leucocytes and platelets concentration for each participant was estimated at Screening, at EOT visit.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  6. Mean Values of Biochemistry Parameters at Screening and Visit 8 (Albumin and Glucose)

    The mean albumin and glucose concentration for each participant was estimated at Screening and at EOT visit.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  7. Mean Values of Cholesterol, Uric Acid, Urea, Creatinine, Calcium, Total Bilirubin and Serum Total Proteins at Screening and EOT Visit.

    The mean concentration of cholesterol, uric acid, urea, creatinine, calcium, total bilirubin and serum total proteins (STP) for each participant was estimated at Screening and at EOT visit.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  8. Mean Values of Potassium, Chlorine, Sodium, and Phosphorus at Screening and EOT Visit

    The mean concentration of potassium, chlorine, sodium and phosphorus for each participant was estimated at Screening and at EOT.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  9. Mean Values of Aspartate Transaminase, Alanine Transaminase, Alkaline Phosphatase, and Lactic Dehydrogenase at Screening and EOT Visit

    The mean aspartate transaminase (AST) and alanine transaminase (ALT), Alkaline phosphatase (AP), and Lactic dehydrogenase (LDH) concentration for each participant was estimated at Screening and at EOT visit.

    Time frame: Screening (Days -28 to 0) and EOT (Week 24)

  10. Mean Duration of Morning Joint Stiffness

    The efficacy of rituximab was assessed by evaluating mean duration of morning joint stiffness.

    Time frame: Screening ((Days -28 to 0), EOT (Week 24), and EOFU (Week 48)

  11. Mean Value of Painful Joints

    The efficacy of rituximab was assessed by evaluating painful joints.

    Time frame: Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)

  12. Number of Participants With American College of Rheumatology (20, 50, and 70) Criteria

    American College of Rheumatology (ACR) criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender joints and swollen joints, as well as for three of the additional five ACR core set variables: patient's assessment of pain using a Visual Analog Scale (VAS) with left end of the line 0=no pain to right end of the line 100=unbearable pain); patient's global assessment of disease activity and physician's global assessment of disease activity using a VAS (0=no disease activity to 100=maximum disease activity); health assessment questionnaire (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant; C-reactive protein and globular sedimentation velocity.

    Time frame: Week 1, Week 12, and Week 24

  13. Mean Value of Quality of Life (Health Assessment Questionnaire - Disease Index)

    Health Assessment Questionnaire - Disease Index (HAQ-DI) indicates how the disease affected participant's activities of daily life. It consisted of 20 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale, 0=without any difficulty to 3=unable to do. Sum of scores was divided by number of domains with a score for a total possible score of 0 (best/no difficulties to perform activities) to 3 (worst/ unable to perform activities at all).

    Time frame: Screening (Days -28 to 0), Week 1, Week 12, and Week 24

  14. Mean Values of C Reactive Protein

    C Reactive Protein (CRP) is a component of ACR. CRP is a marker of inflammation.

    Time frame: Screening ((Days -28 to 0), EOT (Week 24), and EOFU (Week 48)

  15. Mean Values of Globular Sedimentation Velocity

    Globular sedimentation velocity is a component of ACR.

    Time frame: Screening ((Days -28 to 0), Week 1, Week 12, and Week 24

  16. Mean Values of Pain and Activity Based on Visual Analogue Scale

    Pain assessment was assessed by using a VAS (0=no pain to 100=unbearable pain). Disease activity was also evaluated by participants and investigators by using a VAS (0=no disease activity to 100=maximum disease activity).

    Time frame: Screening ((Days -28 to 0), Week 1, Week 12, and Week 24

  17. Mean Value of Inflamed Joints

    The efficacy of rituximab was assessed by evaluating inflamed joints.

    Time frame: Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)

07

Results

Posted Oct 14, 2016

Participant flow

A total of 246 participants were enrolled in study conducted from 20 February 2006 to 05 December 2008 across 56 study centers in 10 Latin American countries.

Participant flow — Overall Study
MilestoneRituximab
Started232
Completed188
Not completed44
Withdrew: Lost to follow-up9
Withdrew: Protocol violation2
Withdrew: Treatment failure25
Withdrew: Withdrawal informed consent6
Withdrew: Adverse event2

Outcome measures

PrimaryNumber of Participants With Any Adverse Event, Any Serious Adverse Event, and Death

An Adverse event (AE) was considered any unfavorable medical event in a participant of clinical research who received the study drug and that not necessarily had a causal relationship with this treatment. An AE could, therefore, being any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. A serious adverse event (SAE) is any experience that suggested a significant risk, contraindication, caution, and at any dose fulfills at least one of the following criteria: adverse event considered as fatal (resulting in death), life threatening, defect of birth/congenital abnormality, required hospitalization or extension of hospital length of stay, significant medical intervention, resulted in significant disability/impairment.

Time frame:
Up to Week 48
Reported as:
Number · participants
Number of Participants With Any Adverse Event, Any Serious Adverse Event, and Death
participantsRituximab
Any AE189
Any SAE12
Death0
PrimaryNumber of Participants With AEs According to Degree of Intensity

An AE is any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. The Intensity of AEs was classified as Grade 1, Grade 2, Grade 3 and Grade 4. Grade 1: Discomfort was noticed, but the normal daily activity was not interrupted. Grade 2: Discomfort was enough to reduce the normal daily activity. Grade 3: There was disability for work or develop normal daily activities. Grade 4: It represented an immediate threat to life (these events were reported as SAEs).

Time frame:
Up to Week 48
Reported as:
Number · participants
Number of Participants With AEs According to Degree of Intensity
participantsRituximab
Grade 1 AEs170
Grade 2 AEs102
Grade 3 AEs30
Grade 4 AEs12
PrimaryNumber of Participants With AEs Leading to Discontinuation and Any Drug Related AEs and SAEs

An AE is any unfavorable sign and non-intentional, symptom or disease temporarily related with the use of a medicinal product, considered or not related to the medicinal product. Pre-existing conditions that worsened during the study were reported as AEs. A SAE is any experience that suggested a significant risk, contraindication, caution, and at any dose, fulfills, at least, one of the following criteria: adverse event considered as fatal (resulting in death), life threatening, defect of birth/congenital abnormality, required hospitalization or extension of hospital length of stay, significant medical intervention, resulted in significant disability/impairment. Relationship between AEs and medication under investigation was evaluated through the classification "Yes" and "No". A relationship classified as "Yes" implied a significant causal relationship with the medication under investigation which was evaluated based on enough evidences, facts or arguments.

Time frame:
Up to Week 48
Reported as:
Number · participants
Number of Participants With AEs Leading to Discontinuation and Any Drug Related AEs and SAEs
participantsRituximab
Any drug related AE97
Any drug related SAE0
Any AE leading to discontinuation2
PrimaryNumber of Participants With AEs of Special Interest During the Study

Adverse event of special interest during the study treatment and follow up period included infections. The participants with AEs of special interest were reported at Screening, End of treatment (EOT), and End of Follow-up (EOFU) visit.

Time frame:
Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Reported as:
Number · participants
Number of Participants With AEs of Special Interest During the Study
participantsRituximab
Screening5
EOT12
EOFU12
SecondaryMean Values of Hematology Parameters at Screening and EOT Visit (Hemoglobin and Mean Corpuscular Hemoglobin Concentration)

The values of hemoglobin (Hb) and mean corpuscular hemoglobin concentration (MCHC) for each participant were estimated at Screening and at EOT visit.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · g/deciliter (dL)
Mean Values of Hematology Parameters at Screening and EOT Visit (Hemoglobin and Mean Corpuscular Hemoglobin Concentration)
g/deciliter (dL)Rituximab
Hb, Screening12.4 ± 1.9
Hb, EOT12.8 ± 1.6
MCHC, Screening30.0 ± 3.6
MCHC, EOT30.9 ± 2.7
SecondaryMean Values of Hematology Parameters at Screening and EOT Visit (Hematocrit, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)

The hematology parameters (hematocrit, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) for each participant were estimated at Screening and at EOT.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · percentage of cells
Mean Values of Hematology Parameters at Screening and EOT Visit (Hematocrit, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)
percentage of cellsRituximab
Hematocrit, Screening37.8 ± 4.2
Hematocrit, EOT38.9 ± 4.3
Neutrophils, Screening67.8 ± 9.4
Neutrophils, EOT65.1 ± 9.9
Lymphocytes, Screening24.0 ± 7.7
Lymphocytes, EOT25.6 ± 8.7
Monocytes, Screening4.3 ± 3.1
Monocytes, EOT5.4 ± 3.6
Eosinophils, Screening1.9 ± 2.0
Eosinophils, EOT2.5 ± 2.0
Basophils, Screening0.2 ± 0.3
Basophils, EOT0.3 ± 0.4
SecondaryMean Values of Hematology Parameter at Screening and EOT Visit (Mean Corpuscular Volume)

Mean corpuscular volume (MCV) is the average volume of red cells. The mean MCV concentration for each participant was estimated at Screening and EOT.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · femtoliters
Mean Values of Hematology Parameter at Screening and EOT Visit (Mean Corpuscular Volume)
femtolitersRituximab
MCV, Screening85.8 ± 8.5
MCV, EOT87.7 ± 7.0
SecondaryMean Values of Hematology Parameter at Screening and EOT Visit (Erythrocytes)

The mean erythrocyte concentration for each participant was estimated at Screening and at EOT.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · 10^12 cells/liter
Mean Values of Hematology Parameter at Screening and EOT Visit (Erythrocytes)
10^12 cells/literRituximab
Erythrocytes, Screening4.5 ± 1.2
Erythrocytes, EOT4.4 ± 0.5
SecondaryMean Values of Hematology Parameters at Screening and EOT Visit (Leucocytes and Platelets)

The mean leucocytes and platelets concentration for each participant was estimated at Screening, at EOT visit.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · 10^9 cells/liter
Mean Values of Hematology Parameters at Screening and EOT Visit (Leucocytes and Platelets)
10^9 cells/literRituximab
Leucocytes, Screening8.6 ± 2.6
Leucocytes, EOT7.7 ± 2.3
Platelets, Screening351.6 ± 112.5
Platelets, EOT310.6 ± 97.1
SecondaryMean Values of Biochemistry Parameters at Screening and Visit 8 (Albumin and Glucose)

The mean albumin and glucose concentration for each participant was estimated at Screening and at EOT visit.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · g/dL
Mean Values of Biochemistry Parameters at Screening and Visit 8 (Albumin and Glucose)
g/dLRituximab
Albumin, Screening3.9 ± 0.5
Albumin, EOT4.1 ± 0.4
Glucose, Screening86.1 ± 12.3
Glucose, EOT88.1 ± 26.5
SecondaryMean Values of Cholesterol, Uric Acid, Urea, Creatinine, Calcium, Total Bilirubin and Serum Total Proteins at Screening and EOT Visit.

The mean concentration of cholesterol, uric acid, urea, creatinine, calcium, total bilirubin and serum total proteins (STP) for each participant was estimated at Screening and at EOT visit.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · mg/dL
Mean Values of Cholesterol, Uric Acid, Urea, Creatinine, Calcium, Total Bilirubin and Serum Total Proteins at Screening and EOT Visit.
mg/dLRituximab
Cholesterol, Screening187.9 ± 42.2
Cholesterol, EOT196.6 ± 42.7
Uric acid, Screening4.0 ± 1.2
Uric acid, EOT4.0 ± 1.1
Urea, Screening29.3 ± 10.0
Urea, EOT30.2 ± 11.0
Creatinine, Screening0.7 ± 0.2
Creatinine, EOT0.7 ± 0.2
Calcium, Screening9.0 ± 1.3
Calcium, EOT9.0 ± 1.0
Total Bilirubin, Screening0.7 ± 1.1
Total Bilirubin, EOT0.7 ± 1.1
STP, Screening7.3 ± 0.6
STP, EOT7.1 ± 0.6
SecondaryMean Values of Potassium, Chlorine, Sodium, and Phosphorus at Screening and EOT Visit

The mean concentration of potassium, chlorine, sodium and phosphorus for each participant was estimated at Screening and at EOT.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · millimoles per liter
Mean Values of Potassium, Chlorine, Sodium, and Phosphorus at Screening and EOT Visit
millimoles per literRituximab
Sodium, Screening140.1 ± 3.3
Sodium, EOT140.4 ± 3.3
Potassium, Screening4.2 ± 0.4
Potassium, EOT4.2 ± 0.4
Chlorine, Screening103.1 ± 4.2
Chlorine, EOT103.3 ± 4.2
Phosphorus, Screening3.7 ± 0.6
Phosphorus, EOT3.8 ± 0.7
SecondaryMean Values of Aspartate Transaminase, Alanine Transaminase, Alkaline Phosphatase, and Lactic Dehydrogenase at Screening and EOT Visit

The mean aspartate transaminase (AST) and alanine transaminase (ALT), Alkaline phosphatase (AP), and Lactic dehydrogenase (LDH) concentration for each participant was estimated at Screening and at EOT visit.

Time frame:
Screening (Days -28 to 0) and EOT (Week 24)
Reported as:
Mean · International units/liter
Mean Values of Aspartate Transaminase, Alanine Transaminase, Alkaline Phosphatase, and Lactic Dehydrogenase at Screening and EOT Visit
International units/literRituximab
AST, Screening21.6 ± 9.7
AST, EOT22.0 ± 9.5
ALT, Screening24.1 ± 14.9
ALT, EOT25.9 ± 14.9
AP, Screening137.7 ± 71.6
AP, EOT138.2 ± 81.7
LDH, Screening311.0 ± 149.1
LDH, EOT300.5 ± 125.4
SecondaryMean Duration of Morning Joint Stiffness

The efficacy of rituximab was assessed by evaluating mean duration of morning joint stiffness.

Time frame:
Screening ((Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Reported as:
Mean · Minutes
Mean Duration of Morning Joint Stiffness
MinutesRituximab
Screening120.1 ± 96.3
EOT16.0 ± 36.5
EOFU19.9 ± 42.4
SecondaryMean Value of Painful Joints

The efficacy of rituximab was assessed by evaluating painful joints.

Time frame:
Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Reported as:
Mean · number of painful joints
Mean Value of Painful Joints
number of painful jointsRituximab
Painful joints, Screening17.5 ± 8.6
Painful joints, EOT3.8 ± 4.9
Painful joints, EOFU4.4 ± 5.7
SecondaryNumber of Participants With American College of Rheumatology (20, 50, and 70) Criteria

American College of Rheumatology (ACR) criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender joints and swollen joints, as well as for three of the additional five ACR core set variables: patient's assessment of pain using a Visual Analog Scale (VAS) with left end of the line 0=no pain to right end of the line 100=unbearable pain); patient's global assessment of disease activity and physician's global assessment of disease activity using a VAS (0=no disease activity to 100=maximum disease activity); health assessment questionnaire (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant; C-reactive protein and globular sedimentation velocity.

Time frame:
Week 1, Week 12, and Week 24
Reported as:
Number · participants
Number of Participants With American College of Rheumatology (20, 50, and 70) Criteria
participantsRituximab
ACR 20, Week 11
ACR 20, Week 1284
ACR 20, Week 2488
ACR 50, Week 10
ACR 50, Week 1250
ACR 50, Week 2462
ACR 70, Week 10
ACR 70, Week 1233
ACR 70, Week 2442
SecondaryMean Value of Quality of Life (Health Assessment Questionnaire - Disease Index)

Health Assessment Questionnaire - Disease Index (HAQ-DI) indicates how the disease affected participant's activities of daily life. It consisted of 20 questions in 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale, 0=without any difficulty to 3=unable to do. Sum of scores was divided by number of domains with a score for a total possible score of 0 (best/no difficulties to perform activities) to 3 (worst/ unable to perform activities at all).

Time frame:
Screening (Days -28 to 0), Week 1, Week 12, and Week 24
Reported as:
Mean · Scores on scale
Mean Value of Quality of Life (Health Assessment Questionnaire - Disease Index)
Scores on scaleRituximab
Screening; n = 1062.6 ± 1.3
Week 1; n = 1142.5 ± 1.4
Week 12; n = 1071.25 ± 1.0
Week 24; n = 1051.0 ± 1.0
SecondaryMean Values of C Reactive Protein

C Reactive Protein (CRP) is a component of ACR. CRP is a marker of inflammation.

Time frame:
Screening ((Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Reported as:
Mean · milligrams per liter
Mean Values of C Reactive Protein
milligrams per literRituximab
Screening28.0 ± 45.3
Week 127.6 ± 56.1
Week 1213.6 ± 25.0
Week 2415.3 ± 45.2
SecondaryMean Values of Globular Sedimentation Velocity

Globular sedimentation velocity is a component of ACR.

Time frame:
Screening ((Days -28 to 0), Week 1, Week 12, and Week 24
Reported as:
Mean · millimeters per hour
Mean Values of Globular Sedimentation Velocity
millimeters per hourRituximab
Screening43.7 ± 22.8
Week 141.1 ± 23.0
Week 1226.8 ± 17.8
Week 2424.6 ± 19.0
SecondaryMean Values of Pain and Activity Based on Visual Analogue Scale

Pain assessment was assessed by using a VAS (0=no pain to 100=unbearable pain). Disease activity was also evaluated by participants and investigators by using a VAS (0=no disease activity to 100=maximum disease activity).

Time frame:
Screening ((Days -28 to 0), Week 1, Week 12, and Week 24
Reported as:
Mean · Scores on scale
Mean Values of Pain and Activity Based on Visual Analogue Scale
Scores on scaleRituximab
Pain, Screening6.9 ± 1.9
Pain, Week 16.9 ± 1.9
Pain, Week 123.6 ± 2.4
Pain, Week 243.0 ± 2.2
Activity (participant), Screening6.6 ± 2.3
Activity (participant), Week 15.9 ± 2.5
Activity (participant), Week 124.7 ± 2.8
Activity (participant), Week 243.9 ± 2.7
Activity (investigator), Screening6.4 ± 2.0
Activity (investigator), Week 16.3 ± 2.1
Activity (investigator), Week 123.9 ± 3.9
Activity (investigator), Week 243.0 ± 2.5
SecondaryMean Value of Inflamed Joints

The efficacy of rituximab was assessed by evaluating inflamed joints.

Time frame:
Screening (Days -28 to 0), EOT (Week 24), and EOFU (Week 48)
Reported as:
Mean · number of inflamed joints
Mean Value of Inflamed Joints
number of inflamed jointsRituximab
Inflamed joints, Screening17.5 ± 8.6
Inflamed joints, EOT3.8 ± 4.9
Inflamed joints, EOFU4.4 ± 5.7

Adverse events

Collected over Up to Week 48. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—12/232 (5.2%)189/232 (81.5%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventRituximab
Abdominal distensionGastrointestinal disorders1/232
Acute gastroenteritisGastrointestinal disorders1/232
Ovarian neoplasm NOSReproductive system and breast disorders1/232
Uterine myomaReproductive system and breast disorders1/232
PneumoniaRespiratory, thoracic and mediastinal disorders1/232
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/232
Tubo-ovarian abscessInfections and infestations1/232
Arthritis aggravatedMusculoskeletal and connective tissue disorders1/232
Cerebral infarctionNervous system disorders1/232
DepressionPsychiatric disorders1/232
Most frequent other events
Showing 10 of 64
Most frequent other events
EventRituximab
HeadacheNervous system disorders40/232
Urinary tract infectionInfections and infestations23/232
NauseaGastrointestinal disorders22/232
DizzinessNervous system disorders17/232
DiarrheaGastrointestinal disorders16/232
DyspepsiaGastrointestinal disorders15/232
ColdRespiratory, thoracic and mediastinal disorders15/232
Upper respiratory tract infection viral NOSInfections and infestations14/232
Hypertension arterialVascular disorders12/232
VomitingGastrointestinal disorders9/232

Baseline characteristics

The safety population included all eligible participants who received one treatment dose of rituximab and have completed the follow up period (Week 48) regardless of whether withdrawn or not from the study.

Age, Continuous
Age, Continuous(years)Rituximab
Mean48.6 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female207
Male25
08

Study locations

50 sites
  • Buenos Aires, 1425, Argentina
  • Buenos Aires, C1280AEB, Argentina
  • Buenos Aires, C1426AAL, Argentina
  • Córdoba, 5000, Argentina
  • San Miguel de Tucuman, 4000, Argentina
  • Tucuman, 4000, Argentina
  • Belem, 66063-240, Brazil
  • Brasilia, 70322000, Brazil
  • Brasilia, 70390-904, Brazil
  • Campinas, 13015-001, Brazil
  • Campinas, 13025-141, Brazil
  • Curitiba, 80730-000, Brazil
  • Florianopolis, 88040-970, Brazil
  • Fortaleza, 60155-290, Brazil
  • Fortaleza, 60430-370, Brazil
  • Goiania, 74110010, Brazil
  • Nova Lima, 34000-000, Brazil
  • Porto Alegre, 90610-000, Brazil
  • Recife, 50000-000, Brazil
  • Ribeirão Preto, 14048-900, Brazil
  • Rio de Janeiro, 20551-030, Brazil
  • Rio de Janeiro, 21941-590, Brazil
  • Rio de Janeiro, 22050-000, Brazil
  • Rio de Janeiro, 22640102, Brazil
  • Salvador, 40050-410, Brazil
  • Sao Paulo, 03128-050, Brazil
  • Sao Paulo, 04026-000, Brazil
  • Sao Paulo, 04038-002, Brazil
  • Sao Paulo, 04038-040, Brazil
  • Sao Paulo, 04039-004, Brazil
  • Sao Paulo, 05403-000, Brazil
  • Vitoria, 29043-910, Brazil
  • Santiago, Chile
  • Barranquilla, Colombia
  • Bogota, Colombia
  • Cuenca, 1394, Ecuador
  • Guayaquil, Ecuador
  • Quito, 1394, Ecuador
  • San Salvador, El Salvador
  • Mexico City, 02990, Mexico
  • Mexico City, 06920, Mexico
  • Mexico City, 14080, Mexico
  • San Luis Potosi, 78240, Mexico
  • Jesus Maria, Peru
  • Lima, 13, Peru
  • San Isidro, LIMA 27, Peru
  • Montevideo, 11600, Uruguay
  • Barquisimeto, 3005, Venezuela
  • Caracas, 1010, Venezuela
  • Caracas, 1040, Venezuela
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2007
First posted
Jul 18, 2007
Start
Feb 2006
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Oct 14, 2016
Last update
Oct 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00502996
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 18, 2007
Start date
Feb 2006
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Oct 14, 2016
Last update
Oct 14, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Rituximab

Start the discussion